Prucalopride Succinate Property

Melting point:

>196°C (dec.)

storage temp. 

Sealed in dry,Room Temperature

solubility 

DMSO (Slightly), Methanol (Slightly)

form 

Solid

color 

White to Pale Brown

InChI

InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)

InChIKey

QZRSNVSQLGRAID-UHFFFAOYSA-N

SMILES

C(O)(=O)CCC(O)=O.O1C2=C(C(NC3CCN(CCCOC)CC3)=O)C=C(Cl)C(N)=C2CC1

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H412Harmful to aquatic life with long lasting effects

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P273Avoid release to the environment.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

Prucalopride Succinate Chemical Properties,Usage,Production

Chemical Properties

Butanedioic acid 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide is Off-White to Pale Brown Solid

Uses

Prucalopride is a selective 5-HT4 receptor agonist used effective for chronic constipation, but is not currently approved in the U.S. Prucalopride is approved for the treatment of chronic constipation in Europe.

Uses

Prucalopride Succinate is the succinate form of prucalopride. It is a selective 5-HT4 receptor agonist used for the treatment of chronic constipation in adults for whom laxatives are not effective. It is not indicated for use in children and adolescents under 18 years of age.

brand name

Motegrity,  Resolor, Resotran

Mechanism of action

The succinate form of prucalopride is an orally bioavailable dihydrobenzofurancarboxamide and selective serotonin (5-HT4) receptor agonist with pro-gastrointestinal motility activity. Upon oral administration, procalcitonin specifically targets, binds and stimulates 5-HT4 receptors. This alters the pattern of colonic motility and stimulates large amounts of peristalsis in the colon. This normalises bowel movements and relieves chronic constipation. In addition, by increasing peristalsis in the oesophagus and stomach, prucalopride also relieves symptoms associated with inhalation.

Clinical Use

Prucalopride succinate, a first-in-class dihydrobenzofurancarboxamide, is a selective serotonin (5- HT4) receptor agonist. The drug, marketed under the brand name Resolor®, possesses enterokinetic activity and was developed by the Belgian-based pharmaceutical firm Movetis. Prucalopride alters colonic motility patterns via serotonin 5-HT4 receptor stimulation, triggering the central propulsive force for defecation.

Side effects

The most common adverse reactions to Prucalopride Succinate include: headache, nausea, diarrhoea and abdominal pain, loss of appetite, dizziness, vomiting, digestive disturbances (dyspepsia), windiness, abnormal bowel sounds, and tiredness. Other side effects that may come out below are: tremor, rapid heartbeat, rectal bleeding, increased urination (pollenuria), fever, overall general feeling of malaise, flatulence. Severe allergic reactions are rare and manifest as hives or lumps, itching, rash，redness of the skin, facial swelling, and chest tightness. Contact your doctor if any of these serious adverse reactions occur.

Synthesis

The preparation of prucalopride succinate begins with the commercially available salicylic aniline 124. Acidic esterification, acetylation of the aniline nitrogen atom, and ambient-temperature chlorination via sulfuryl chloride (SO2Cl2) converted aminophenol 124 to acetamidoester 125 in 83% yield over the course of three steps. An unique set of conditions involving sodium tosylchloramide (chloramine T) trihydrate and sodium iodide were then employed to convert 125 to o-phenolic iodide 126, which then underwent sequential Sonogashira/cyclization reaction utilizing TMS-acetylene with tetramethylguanidine (TMG) in the presence of silica gel to furnish the benzofuran progenitor of 127. Hydrogenation of this intermediate benzofuranyl Sonagashira product saturated the 2,3-benzofuranyl bond while leaving the chlorine atom intact, ultimately delivering dihydrobenzofuran 127 in excellent yield for the two step sequence. Base-induced saponification and acetamide removal gave rise to acid 128. This acid was activated as the corresponding mixed anhydride and treated with commercial piperidine 129 to construct prucalopride which was stirred at room temperature for 24 hours in ethanolic succinic acid to provide prucalopride succinate (XI). The yield for the formation of the salt was not provided.